

Miller, Diane M. (CDC/NIOSH/EID)

From: Noreen.Kishimoto@kp.org
Sent: Wednesday, June 10, 2009 3:15 PM
To: NIOSH Docket Office (CDC)
Subject: 105a - Haz Drug Appx A Rev

The proposed addition of infliximab (Remicade) is not consistent with the proposed deletions of Orencia, Rituxan, Tysabri, Erbitux & Avastin. Remicade has been on the market for many years and I am not aware of any new formulation or change that would warrant its' addition to the Hazardous list. It should remain off the list and the other monoclonal antibodies should be removed.

Respectfully,

Noreen Kishimoto
Pharmacy Supervisor (Home IV, Englewood Infusion Ctr)
(303) 344-7011
Blackberry (303) 525-8733
Fax (303) 344-7048
Kaiser Permanente of Colorado

NOTICE TO RECIPIENT: If you are not the intended recipient of this e-mail, you are prohibited from sharing, copying, or otherwise using or disclosing its contents. If you have received this e-mail in error, please notify the sender immediately by reply e-mail and permanently delete this e-mail and any attachments without reading, forwarding or saving them. Thank you.